1. Home
  2. SOS vs MEIP Comparison

SOS vs MEIP Comparison

Compare SOS & MEIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SOS
  • MEIP
  • Stock Information
  • Founded
  • SOS 2004
  • MEIP 2000
  • Country
  • SOS China
  • MEIP United States
  • Employees
  • SOS N/A
  • MEIP 28
  • Industry
  • SOS Finance: Consumer Services
  • MEIP Biotechnology: Pharmaceutical Preparations
  • Sector
  • SOS Finance
  • MEIP Health Care
  • Exchange
  • SOS Nasdaq
  • MEIP Nasdaq
  • Market Cap
  • SOS 21.7M
  • MEIP 17.3M
  • IPO Year
  • SOS 2017
  • MEIP 2003
  • Fundamental
  • Price
  • SOS $6.09
  • MEIP $2.60
  • Analyst Decision
  • SOS
  • MEIP Hold
  • Analyst Count
  • SOS 0
  • MEIP 2
  • Target Price
  • SOS N/A
  • MEIP $7.00
  • AVG Volume (30 Days)
  • SOS 18.4K
  • MEIP 7.5K
  • Earning Date
  • SOS 09-24-2024
  • MEIP 02-12-2025
  • Dividend Yield
  • SOS N/A
  • MEIP N/A
  • EPS Growth
  • SOS N/A
  • MEIP N/A
  • EPS
  • SOS N/A
  • MEIP N/A
  • Revenue
  • SOS $111,124,000.00
  • MEIP N/A
  • Revenue This Year
  • SOS N/A
  • MEIP N/A
  • Revenue Next Year
  • SOS N/A
  • MEIP N/A
  • P/E Ratio
  • SOS N/A
  • MEIP N/A
  • Revenue Growth
  • SOS N/A
  • MEIP 33.76
  • 52 Week Low
  • SOS $5.70
  • MEIP $2.30
  • 52 Week High
  • SOS $60.57
  • MEIP $4.42
  • Technical
  • Relative Strength Index (RSI)
  • SOS 37.44
  • MEIP 37.79
  • Support Level
  • SOS $5.70
  • MEIP $2.55
  • Resistance Level
  • SOS $6.30
  • MEIP $2.79
  • Average True Range (ATR)
  • SOS 0.39
  • MEIP 0.14
  • MACD
  • SOS -0.00
  • MEIP -0.02
  • Stochastic Oscillator
  • SOS 30.23
  • MEIP 14.71

About SOS SOS Limited

SOS Ltd is a multifaceted company that leverages the power of big data to provide marketing solutions, while also participating in the burgeoning fields of blockchain and cryptocurrency operations, as well as commodity trading. Its product offerings are diversified across four main areas: commodity trading, insurance marketing, cryptocurrency mining, and other service. The company has has three reporting segments: Commodity trading, Cryptocurrency mining and Others. Key revenue is generated from Commodity trading.

About MEIP MEI Pharma Inc.

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

Share on Social Networks: